NASDAQ: CLPTClearpoint Neuro Inc Stock
$6.20-0.20 (-3.13%)
Updated May 17, 2024
CLPT Price
$6.20
Fair Value Price
N/A
Market Cap
$170.01M
52 Week Low
$4.05
52 Week High
$8.68
P/E
-7.47x
P/B
4.92x
P/S
6.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.16M
Earnings
-$20.63M
Gross Margin
57.1%
Operating Margin
-79.88%
Profit Margin
-78.8%
Debt to Equity
0.55
Operating Cash Flow
-$12M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLPT Overview
ClearPoint Neuro, Inc. is a medical device company developing platforms for performing minimally invasive surgical procedures in the brain under direct and intra-procedural magnetic resonance imaging (MRI ) guidance. It offers the ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters, into the brain. The ClearPoint Neuro Navigation System is an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, and others. ClearPoint Neuro was incorporated in 1998 and is headquartered in Solana Beach, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLPT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLPT is poor value based on its book value relative to its share price (4.92x), compared to the US Medical Devices industry average (4x)
P/B vs Industry Valuation
CLPT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CLPT due diligence checks available for Premium users.
Be the first to know about important CLPT news, forecast changes, insider trades & much more!
CLPT News
Valuation
CLPT fair value
Fair Value of CLPT stock based on Discounted Cash Flow (DCF)
Price
$6.20
Fair Value
-$0.02
Undervalued by
29,457.16%
CLPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLPT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.47x
Industry
30.6x
Market
30.97x
CLPT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.92x
Industry
4x
CLPT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLPT's financial health
Profit margin
Revenue
$7.6M
Net Income
-$4.1M
Profit Margin
-54.3%
CLPT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CLPT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.6M
Liabilities
$19.1M
Debt to equity
0.55
CLPT's short-term assets ($47.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLPT's short-term assets ($47.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLPT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
$0.0
Financing
$16.1M
CLPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLPT vs Medical Device Stocks
Clearpoint Neuro Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.